Process for the preparation of a galacto-oligosaccharide preparation, which process comprises the step of contacting a lactulose-containing feed with a beta-galactosidase derived from Papiliotrema terrestris. The resulting galacto-oligosaccharide is acceptable to subjects suffering from GOS-related allergy and subjects having lactose intolerance.

The present invention describes a intracellular produced lactase, which comprises less than 40 units arylsulfatase activity per NLU of lactase activity. The invention also provides a process comprising treating a substrate with an enzyme preparation, wherein the enzyme preparation is substantially free from arylsulfatase.

The present invention relates to a sterile-filtered liquid lactase preparation and to a method of sterile filtering a liquid lactase preparation.

The present invention relates to novel lactase variants having improved properties relative to the parent lactase, such as decreased galactose inhibition or increased galactose inhibition. The variants of the invention are suitable for production of dairy products, such as low-lactose dairy products or lactose-free dairy products. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the lactase variants of the invention.

The present invention relates to new improved peptide or dimeric peptides exhibiting beta- galactosidase enzyme activity as well as improved methods for reducing the lactose content in compositions in particular at low temperatures.

New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, new organisms, and a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related to novel cell culture methods and conditions that can be used to express heterologous polypeptides, along with new transgenic yeast strains.

Described herein are compositions and methods related to use of cardiosphere-derived cells and their extracellular vesicles, such as exosomes and microvesicles, for achieving anti-aging and rejuvenation. This includes discoveries for effects on heart structure, function, gene expression, and systemic parameters. For animal studies, intra-cardiac injections of neonatal rat CDCs was compared to in old and young rats including evaluation of blood, echocardiographic, haemodynamic and treadmill stress tests. For in vitro studies, human heart progenitors from older donors, or cardiomyocytes from aged rats were exposed to human CDCs or cardiosphere derived cell (CDC) derived exosomes (CDC-XO) from pediatric donors. CDCs and CDC-XOs were capable of effectuating youthful patterns of gene expression in the hearts of old, along with a variant of physiological and function benefits, including elongation of telomere length. Together, these results indicate capacity of CDCs and CDC-XO to ward off the effects of aging through rejuvenation.

Suggested is method for producing galactooligosaccharides, comprising the following steps:

(i) Providing an aqueous milk sugar solution; (ii) Sterilising the milk sugar solution; (iii) Performing a transgalactosilation of the milk sugars present in the sterilised milk sugar solution of step (ii) by adding at least one beta-galactosidase within its optimum temperature and pH value intervals for a period of at least 30 minutes, obtaining a reaction mixture; (iv) Inhibiting the enzyme mass in the reaction mixture of step (iii), and (v) Confectioning the reaction mixture of step (iv), Wherein (a) The enzyme mass is wholly or partly inhibited by setting a pH value outside the activity optimum of the enzymes; (b) The reaction mixture, together with the inhibited enzyme mass, is subjected to filtration, obtaining a retentate (R1) and a permeate (P1); (c) The inhibited amount of enzymes is separated as a retentate (R1) and is fed back to step (iii); and (d) The permeate (P2) containing the galactooligosaccharides is passed on to step (v).

The invention relates to the field of nutritional ingredients, in particular to methods for producing hypoallergenic galacto-oligosaccharides (GOS) and the use thereof in food and drink items. Provided is the use of a beta-galactosidase (EC 3.2.1.23) derived from Cryptococcus terrestris (recently renamed Papiliotrema terrestris) in the production of a hypoallergenic GOS preparation having a reduced capacity to induce an allergic response in a subject.

Disclosed herein is a process for producing a peanut milk product, which includes subjecting a milk material to a hydrolysis reaction with lactase and transglucosidase to obtain a milk product, immersing peanut kernels in water to obtain swelled peanut kernels, subjecting the swelled peanut kernels to a steam cooking treatment to obtain steamed peanut kernels, and admixing the milk product with the steamed peanut kernels, followed by subjecting a mixture thus obtained to a heating treatment, so as to obtain the peanut milk product. A method for improving gut health using the peanut milk product and a canned food containing the peanut milk product are also disclosed.